FierceBiotech offering a free eBook on moving along the path from Preclinical to Clinical
Drugmakers face slim odds of a compound entering clinical trials ever becoming a marketed drug: an abysmal 1-in-10 shot at success. To boost their win ratio, pharma leaders have called for intense studies of drug toxicity and disease biology before compounds enter human trials. Learn how the industry has re-emphasized translational medicine to usher molecules from preclinical development to initial human studies.
By providing deep dives on timely industry issues, Fierce eBooks are valuable educational tools. They are designed to be easily read online — but also are formatted so you can print them out and take them with you. Fierce ebooks are assembled like a magazine, read the whole thing cover-to-cover, or pick and choose the articles that interest you most. Either way, they’re a great one-stop resource.